StockData
Rigel Pharmaceuticals Inc logo

Rigel Pharmaceuticals Inc (RIGL) stock

RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$42.92−0.81 (-1.85%)

Close on Nov 17, 2026Market cap $801.74MP/E 2.7Yield –

Rigel Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Rigel Pharmaceuticals's price to sales ratio was 3.2× on Nov 11, 2026, against 3.3× a year earlier. Over the last 5 years it ranged from 1.1× to 3.6×, with a median of 2.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.2×+0.4
2025Dec 31, 20252.8×+0.9
2024Dec 31, 20241.9×−0.0
2023Dec 29, 20231.9×−0.9
2022Dec 30, 20222.8×−0.3
2021Dec 31, 20213.1×−2.5
2020Dec 31, 20205.6×+1.2
2019Dec 31, 20194.4×−60.4
2018Dec 31, 201864.8×+46.8
2017Dec 29, 201718.0×–

More Rigel Pharmaceuticals figures

See a number that looks wrong?